Last updated: February 22, 2026
What is DIATRIZOATE MEGLUMINE?
Diatrizoate Meglumine is a contrast agent used in diagnostic imaging procedures. It belongs to the iodinated contrast media class, designed to enhance radiographic images during procedures such as computed tomography (CT), angiography, and myelography. The compound's primary function is to improve visualization of blood vessels, tissues, and organs.
Market Overview
The global iodinated contrast media market was valued at approximately USD 2.45 billion in 2022. It is projected to reach USD 3.3 billion by 2030, expanding at a compound annual growth rate (CAGR) of around 4.2% from 2023 to 2030 [1].
Key drivers include increased prevalence of cardiovascular and neurological diseases, rising adoption of advanced imaging techniques, and technological advancements expanding contrast media indications.
Regulatory Status and Approvals
Diatrizoate Meglumine is approved in multiple jurisdictions, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). It is marketed under various brand names, including Hypaque and Urografin.
The U.S. FDA approved Urografin (diatrizoate meglumine and sodium amidotrizoate) with indications for diagnostic imaging since the 1960s. Approval clarity is consistent across the EU, with restrictions primarily related to contraindications and adverse reactions.
Patent and Market Exclusivity Landscape
Many formulations of Diatrizoate Meglumine are off-patent or have expired patents, leading to a highly commoditized market environment. Existing patents on specific formulations or delivery systems have expired or are close to expiration, limiting exclusivity opportunities.
Patent Status Summary:
| Patent Type |
Status |
Expiry Year |
Notes |
| Composition patents |
Expired |
2015-2020 |
No longer enforceable in key markets |
| Process patents |
Expired |
2018 |
Limited influence on current market |
| Formulation patents |
Expired |
Past dates |
No current protection, high generic entry |
But generic competition is high, with multiple manufacturers producing comparable contrast agents.
Competitive Landscape
Major players include:
- Bracco Imaging
- GE Healthcare
- Guerbet
- Bayer
- Fujifilm
Generic manufacturers supply low-cost alternatives, exerting downward pressure on prices.
R&D and Innovation
Despite high competition, innovation focuses on:
- Developing lower-osmolar contrast agents (e.g., iso-osmolar, low-osmolar variants) that reduce adverse effects.
- Formulating improved delivery systems.
- Creating products with better tissue compatibility and fewer allergic reactions.
The development pipeline is sparse for new iodine-based contrast media, with most efforts directed toward reformulation rather than novel compounds.
Pricing and Cost Dynamics
The average price per dose of Diatrizoate Meglumine varies by region:
| Region |
Price per Dose |
Major Factors |
| U.S. |
USD 10-15 |
Brand versus generic, insurance coverage |
| Europe |
USD 8-12 |
Reimbursement systems, hospital contracts |
| Asia |
USD 3-7 |
Market saturation, local competition |
Price sensitivity remains high, influenced by insurance coverage, healthcare policies, and availability of generics.
Investment Considerations
Growth Potential
- Market growth driven by increased imaging procedures, particularly CT scans.
- Price erosion due to generic competition limits profit margins.
- Innovations improving safety profiles may command premium pricing, but pipeline activity is limited.
Risks
- Patent expirations diminish barriers to entry.
- Regulatory restrictions on iodine-based contrast agents due to adverse effects.
- Competitive landscape dominated by large players with mature portfolios.
- Volatile global supply chains affecting raw materials and manufacturing.
Opportunities and Barriers
- Opportunities: Niche formulations with better safety; regional expansion in emerging markets.
- Barriers: High R&D costs for reformulation and regulatory approval; entrenched commoditized market.
Regulatory and Policy Impact
Increasing scrutiny on contrast agents' safety impacts market dynamics. Regulatory agencies have mandated stricter warnings for allergic reactions and contrast-induced nephropathy, adding compliance costs and complicating new product development.
Final Assessment
Diatrizoate Meglumine's prospects for investment are limited in new product development due to patent expirations and intense generic competition. The current market favors established incumbents and low-cost generics. Innovation efforts focus on reformulation for safety rather than novel compounds.
Key Takeaways
- The drug's patent landscape indicates no exclusivity for new entrants.
- Market growth is substantial but saturated with low-margin generics.
- Innovation emphasizes safety improvements over novel chemistry.
- Price sensitivity and regulatory challenges influence profitability.
- Opportunities exist in regional expansion and safety-focused formulations.
FAQs
1. Is there potential for new patent protection on Diatrizoate Meglumine formulations?
Potential exists for reformulation or delivery system patents, but most original patents expired years ago, reducing pipeline exclusivity.
2. How do regulatory changes affect the market for contrast agents?
Increased safety regulations raise compliance costs and may limit usage in certain patient populations, impacting sales.
3. What is the outlook for generic manufacturers of Diatrizoate Meglumine?
They will continue to dominate due to low entry barriers and high price sensitivity, constraining margin expansion.
4. Are there unmet medical needs related to contrast agents?
Yes, safer alternatives with fewer adverse reactions are in demand, but development is limited to reformulation rather than new compounds.
5. What are the key factors influencing investment decisions in this market?
Market saturation, patent expirations, regulatory environment, safety concerns, and the pace of innovation are critical.
References
[1] Grand View Research. (2022). Iodinated Contrast Media Market Size, Share & Trends Analysis Report.
